Russo, D
Malagola, M
Skert, C
Cancelli, V
Turri, D
Pregno, P
Bergamaschi, M
Fogli, M
Testoni, N
De Vivo, A
Castagnetti, F
Pungolino, E
Stagno, F
Breccia, M
Martino, B
Intermesoli, T
Cambrin, G R
Nicolini, G
Abruzzese, E
Tiribelli, M
Bigazzi, C
Usala, E
Russo, S
Russo-Rossi, A
Lunghi, M
Bocchia, M
D'Emilio, A
Santini, V
Girasoli, M
Lorenzo, R Di
Bernardi, S
Palma, A Di
Cesana, B M
Soverini, S
Martinelli, G
Rosti, G
Baccarani, M
Article History
Received: 14 July 2015
Accepted: 21 July 2015
First Online: 18 September 2015
Competing interests
: Domenico Russo, Patrizia Pregno and Simona Soverini receives compensation as a consultant for Novartis, Bristol-Myers Squibb and Ariad. Elisabetta Abruzzese receives compensation as a consultant for Ariad, Bristol-Myers Squibb, Novartis, Takeda and Pfizer. Giovanni Martinelli receives compensation as a consultant for Novartis, Bristol-Myers Squibb and Pfizer. Gianantonio Rosti, Fausto Castagnetti and Michele Baccarani receives compensation as a consultant for Novartis, Ariad, Bristol-Myers Squibb and Pfizer. Mario Tiribelli receives compensation as a consultant for Novartis, BMS and Ariad. The remaining authors declare no conflict of interest.